Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor.

  title={Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor.},
  author={Yuji Hitomi and Setsuro Ebiya-Cho Fujii},
  journal={International archives of allergy and applied immunology},
  volume={69 3},
  • Y. Hitomi, S. Fujii
  • Published 1 July 1982
  • Chemistry, Medicine
  • International archives of allergy and applied immunology
FUT-175 (6 amidino-2-naphthyl-4-guanidino benzoate-dimethanesulfonate), a new synthetic protease inhibitor, inhibits the enzyme activities of various proteases, such as Clr, C1 esterase, thrombin, kallikrein, plasmin and trypsin. FUT-175 strongly inhibited complement-medicated hemolysis via the classical and alternative pathways. The effects of FUT-175 on various immunological reactions in vivo were studied. The minimal effective dose of FUT-175 in systemic Forssman shock in guinea pigs was 6… 
Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.
FUT-175 was highly effective in that, for example, intravenous dosing at 3 mg/kg could completely protect guinea pigs from the lethal Forssman shock and was also found to be effective in trypsin-induced shock in mice, in lethality due to thrombin-thrombosis in mice and in kinin formation in the inflammatory process in rats.
Inhibitory effects of FUT-175, a new synthetic protease inhibitor, on intravascular hemolysis by human serum in mice.
Results indicated that FUT-175 prevents intravascular hemolysis of mouse erythrocytes through the inhibitory effect of both alternative and classical complement pathway.
Effects of FUT-175, a novel synthetic protease inhibitor, on the development of adjuvant arthritis in rats and some biological reactions dependent on complement activation.
The results suggest that the anti-inflammatory activity of FUT-175 may differ from indomethacin in the mechanisms of action and, at least in part, due to theAnti-complement activity.
The Arthus Reaction in Rodents: Species-Specific Requirement of Complement1
The data support the proposal that complement-mediated processes are of major importance in the Arthus reaction in rats and guinea pigs, and suggest that BCX 1470 will be useful as an anti-inflammatory agent in diseases where complement activation is known to be detrimental.
Immunopharmacological studies on TBX, a new antiallergic drug (4). Effects on type II to IV allergic reactions and immunological functions in animal models.
TBX is an antiallergic drug essentially devoid of inhibitory actions on types II to IV allergic reactions and immunological functions, thus indicating that it is a specific inhibitor of type I allergic reactions.
Elevated kallikrein activity in plasma from stable liver transplant recipients.
The results suggest that elevation in plasma peptidase activity and activation of complement do signal different pathological events in LTR, events that appear related to HCV-induced infection and immune tissue injury, respectively.
Effects of protease inhibitor and immunosuppressant on cerebral vasospasm after subarachnoid hemorrhage in rabbits.
The possible role of the immune-defense system in the development of cerebral vasospasm after subarachnoid hemorrhage (SAH) was investigated in rabbits and the contrasting effects of the two serine protease inhibitors, GM and FUT-175, are discussed.
Prevention of complement-mediated immune hemolysis by a small molecule compound.
Treatment of mice with a 549Da compound significantly prolonged the survival of transfused RBCs, reducing C3 deposition, but not the deposition of control IgG or IgM, for the first hour post-transfusion, suggesting that further studies are warranted to determine if this compound has usefulness in a transfusion setting.
Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospasm in rabbits.
The results indicate that the inhibition of the plasma serine protease cascades at an early stage of SAH prevents the development of cerebral vasospasm.
Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage.
It is suggested that FUT-175 has an additive effect to OKY-046 in preventing vasospasm in high risk patients with severe SAH and when patients of Hunt and Hess grade 5 were excluded, the FUT group had a significantly improved outcome.